Conference Call Presentation July 18, 2019 Forward Looking - - PowerPoint PPT Presentation

▶
conference call presentation july 18 2019 forward looking
SMART_READER_LITE
LIVE PREVIEW

Conference Call Presentation July 18, 2019 Forward Looking - - PowerPoint PPT Presentation

Apr 05, 2023 244 likes •516 views

SEOVF TRADED ON The Path To A Regenerative Cure Conference Call Presentation July 18, 2019 Forward Looking Statement This presentation may contain forward looking statements. Forward-looking statements address future events and

slide-1
SLIDE 1

Conference Call Presentation July 18, 2019

The Path To A Regenerative Cure

TRADED ON

SEOVF

slide-2
SLIDE 2

Forward Looking Statement

This presentation may contain forward looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The information does not constitute any advice, promise or

  • bligation of Sernova Corp. and does not necessarily represent the most current

source of company information. Sernova Corp. cannot, and does not, guarantee or ensure either the accuracy, completeness, or authenticity of this presentation’s contents and may make changes and revisions to the information on this presentation at any time and without notice. The information is presented and stored on an "as is" basis and the use of the presentation to collect information is completely at your own risk. This presentation contains information about third-parties merely as a

  • convenience. The inclusion of such information does not imply that Sernova Corp.

endorses or accepts any responsibility for the content or use of such information. For more information on Sernova Corp, investors should review filings available at www.sedar.com.

2

slide-3
SLIDE 3

Our Mission

Sernova is a clinical stage regenerative medicine therapeutics company developing a Cell Pouch implantable device with therapeutic cells. Our primary focus is development of treatments for patients with insulin-dependent diabetes (T1), hemophilia A and thyroid disease Sernova is currently conducting a U.S. Phase I/II clinical trial targeting an indication

  • f high risk type 1 diabetes with an unmet need called hypoglycemia unawareness

as a first approach for our therapeutic Cell Pouch technologies

slide-4
SLIDE 4

Sernova Share Structure

4

Sernova Corp Founded in 2006 Common Shares 172,237,348 Current Price 0.22 Market Cap 37,9 M 52 Week Range $0.145-$0.27 Transfer Agent AST Trust Company

slide-5
SLIDE 5

Management Team

5

  • Dr. Philip Toleikis

PRESIDENT AND CEO >20 years experience. Joined Sernova

  • 2009. Previous Angiotech VP R&D

(achieved $2.0B market cap; Product Revenue $200M/yr, drug/device combination products).

Sean Hodgins

CA-CPA, CFO >20 years experience in biotech

  • industry. Joined Sernova in 2018. US

and Canada experience with both Nasdaq and TSX experience. Board of Directors

  • Frank Holler
  • Jeffrey Bacha
  • James Parsons
  • Deborah Brown
slide-6
SLIDE 6

40% 32% 28%

Sernova’s Approach

6

To inspire hope and contribute to health and well-being by providing the best care to every patient

Top Notch Doctors

A Total Regenerative Medicine Solution for the Therapeutic Treatment of Chronic Diseases

Cell Pouch™ Therapeutic Cells Immune Protection

Immune Protection

Technologies to protect therapeutic cells from immune system attack

Cell Pouch

An implantable medical device which provides a vascularized environment for therapeutic cells

Therapeutic Cells

Cells that produce and release missing (or needed) proteins or hormones into the bloodstream

slide-7
SLIDE 7

CELL POUCH CANDIDATE PRE- CLINICAL PHASE I PHASE II PHASE III DEVELOPMENT STAGE INDICATION

P H A S E I / I I I N I T I AT E D D E C 2 0 1 8 H Y P O G L Y C E M I A U N A W A R E N E S S H U M A N D O N O R I S L E T S , S Y S T E M I C I M M U N E P R O T E C T I O N M I C R O E N C A P S U L A T E D I S L E T S A N T I C I PAT E D 2 N D A P P R O VA L F O R D I A B E T E S H Y P O G L Y C E M I A U N A W A R E N E S S M I C R O E N C A P S U L A T E D S T E M C E L L D E R I V E D C E L L S A N T I C I PAT E D 3 R D A P P R O VA L F O R D I A B E T E S A L L I N S U L I N D E P E N D E N T D I A B E T I C P A T I E N T S P R E C L I N I C A L S E V E R E H E M O P H I L I A A P A T I E N T S C O R R E C T E D P A T I E N T C E L L S A L L O G R A F T I M M U N E P R O T E C T E D C E L L S E A R L Y D E V E L O P M E N T B R O A D E R H E M O P H I L I A A P A T I E N T S P R E - C L I N I C A L T H Y R O I D E C T O M Y P A T I E N T S F O L L O W I N G H Y P E R T H Y R O I D I S M T H Y R O I D C E L L S

Sernova Pipeline

7

TYPE 1 DI ABETES HEM O PHI LI A A THYRO I D DI SEASE

slide-8
SLIDE 8

Cell Pouch Human Clinical Evaluation

slide-9
SLIDE 9

9

“Hypoglycemia unawareness” affects about 10% of Type 1 Diabetes patients or about 125k patients in the US

  • Clinically defined as a complication of diabetes in which the patient is unaware of a deep drop in

blood sugar levels

  • Failure to trigger secretion of epinephrine a/k/a the symptoms of hypoglycemia (Palpitations, Anxiety,

Excessive Sweating, Light Headedness)

  • Patients live in constant fear of their next diabetic episode

Type 1 Diabetes: 1st Clinical Indication

slide-10
SLIDE 10

Study Design

  • Diabetes subjects with hypoglycemia unawareness
  • Open-label; single-arm
  • Donor islet transplantation 2-24 weeks post Cell Pouch™ implantation
  • Primary endpoint
  • Safety post Cell Pouch™ implantation and 1 month post islet transplantation

Cell Pouch™ and Islet Safety Met

  • Safety successfully met for the Cell Pouch™
  • Cell Pouch™ histology assessed by independent

pathologists blinded to the treatment

  • Islets housed within a natural tissue matrix
  • Islets are well-vascularized
  • Islet safety successfully met
  • Islets show evidence of insulin, somatostatin, & glucagon
  • Cell Pouch™ and islet biocompatibility met
  • Proof of islet protection from immune system attack

10

Type 1 Diabetes : First-in-Human Study

2015

slide-11
SLIDE 11

11

Type 1 Diabetes : First-in-Human Study

slide-12
SLIDE 12

Chicago Phase I/II Study

slide-13
SLIDE 13

Phase I/II U.S. FDA Cleared Study

13

Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch™ for Clinical Islet Transplantation Study design: A open-label, single-arm study of Sernova Cell Pouch implanted with islets. Islets are transplanted into

the Cell Pouch after implantation and stable antirejection medication activity

Primary Objective: To demonstrate the safety and tolerability of islet transplantation into the Cell Pouch for the

treatment of TID in subject with hypoglycemia unawareness and a history of severe hypoglycemic episodes.

Secondary Objectives: To establish islet release criteria that accurately characterize the islet product and are

predictive of clinical transplant outcomes into the Cell Pouch, which will be demonstrated through defined efficacy measures

  • Survival of endocrine tissue in the Cell Pouch
  • Proportion of subjects with a reduction in severe hypoglycemic events
  • Proportion of subjects with a reduction in HbA1c >1mg%
  • Over 20 additional endpoint analyses will occur

Status: US IND Cleared by FDA and IRB and patient enrolment initiated; Medtronic Minimed, Northridge, CA CGM is

supplying patients in Sernova’s U.S. regenerative medicine clinical trial of its Cell Pouch ; Next step: Interim safety and efficacy results

slide-14
SLIDE 14

2nd Islet Transplant

(increase dose)

Phase I/II Timeline

14

Cell Pouch™ Implantation 1st Islet Dose Transplant Immuno Suppression Introduced

Feb 2019 Day180 Day365

3-4 weeks

Primary Endpoint: Initial Topline Safety Readout Small

(sentinel)

Pouches Removed Survival of Endocrine Tissue & Identification of Hormones Reduction in hypoglycemic events Reduction in HbA1c Secondary Endpoints:

Apr 2020

90 Days 3weeks

Immunosuppression Stabilized Cell Pouch Vascularization

90 Days

Additional Safety Assessments Completed Days 30, 60, 270 Post-Transplant

90 Days 90 Days

Day365 Day 0 Day180 Day0 Nov 2020

Safety Efficacy

slide-15
SLIDE 15

Case Report of the First Treated Patient

slide-16
SLIDE 16

Safety- incidence and severity of adverse events determined to be probable or highly probable to the Cell Pouch™ 1. No incidences of AEs, determined to be probable or highly probable to the Cell Pouch™ 2. Cell Pouch™ well-tolerated and safe during the implant and the time of transplant 3. No reactions to the Cell Pouch™ implant 4. Cell Pouch™ was well-incorporated with vascularized tissue and deemed suitable to receive the islet transplant

These interim safety data meet the first measure of the primary endpoint

Primary Endpoint- Safety Measures

Patient Number 1: Interim Findings

slide-17
SLIDE 17

To establish islet release criteria that:

  • 1. accurately characterize the islet product and
  • 2. are predictive of clinical transplant outcomes into the Cell Pouch™, which will be

demonstrated through defined efficacy measures Survival of endocrine tissue in the Cell Pouch™ Proportion of subjects with a reduction in severe hypoglycemic events Proportion of subjects with a reduction in HbA1c >1mg% Over 20 additional endpoint analyses

Secondary Objectives/ Endpoints

slide-18
SLIDE 18

First Patient Initial Efficacy Results

18

PRE ISLET TRANSPLANT 3 MONTHS POST TRANSPLANT BODYWEIGHT 83KG 73KG HEMOGLOBIN A1C 6.5 5.6* DAILY USE OF LONG ACTING INSULIN TRESIBA 14 U 8U* DAILY USE OF SHORT ACTING INSULIN 15-16 14-15* SEVERE HYPOGLYCEMIC EVENTS 6-9/ 3months 1/ 3months* 90 Day Post-Transplant Glucose Tolerance Test Patient is given a high sugar

  • drink. C-peptide and insulin

response is measured over several hours

  • Showed increase in blood

levels of C-Peptide

  • Showed increase in blood

levels of Insulin and a typical insulin response

  • Conclusion: Definitive

proof that the Cell Pouch islets are surviving and able to respond to high levels of sugar by releasing insulin

* Showed improvement with transplanted Cell Pouch

slide-19
SLIDE 19

Comparison between baseline and post transplant parameters Usability

Performance Cell Pouch™ for Islet Transplantation Parameter

Highest Sensor Glucose Value (mg/dL) Lowest Sensor Glucose Value (mg/dL) # High Excursions Standard Deviation (Variability) # Low Excursions

1 66 285 50 7 8 37 231 2 31

Baseline Post Transplant # Glucose Excursions

15 3

CONTINUOUS GLUCOSE MONITOR: IMPROVEMENT IN ALL GLUCOSE PARAMETERS SEEN POST TRANSPLANT

BASELINE CGM

More excursions, hyper/hypo events Less time in range

CGM POST CELL POUCH ISLET TRANSPLANT

Less excursions, hyper/hypo events More time in range

Time above 180 mg/dL Time in Range of 70-180 mg/dL Time below 70 mg/dL

slide-20
SLIDE 20

20

Transplanted Cell Pouch Showed the Following Improvements Relative to Baseline

  • 90-day improvement in Hemoglobin HbA1c
  • 90-day reduction in use of daily long acting insulin
  • Continuous Glucose Monitor Assessment

Improvement in all glucose control parameters measured by continuous glucose monitoring Reduction in severe hypoglycemic events 87.5% reduction in overall hypoglycemic events Time below 70mg/dL: 12% control versus 1% post-Cell Pouch Islets

  • 90-day Glucose Tolerance Test

Showed typical insulin release curve Showed C-Peptide blood levels Conclusion: Cell Pouch with islets is producing blood levels of insulin and showing the ability to have blood sugar control in initial assessments

Summary

slide-21
SLIDE 21

Future Developments / Additional Programs

slide-22
SLIDE 22

Hemophilia Program

Patient Population

  • Hemophilia A ≈ 20,000 NA/EU ($15B Orphan Indication)

Hemophilia Therapy

  • Factor VIII Gene corrected cells within Cell Pouch – produce constant

therapeutic Factor VIII levels

  • Patient corrected cells (autologous)
  • Stem cell derived technology and local immune protection (allograft)

Therapeutic Goals:

  • Improved efficacy with prophylactic treatment reduced cost; improved

patient QOL; reduction of disease side effects Sernova’s Product Approach

  • Corrected own patient cells into the Cell Pouch (Horizon 2020 Grant)
  • Status: Corrected patient cells survive and produce Factor VIII in

hemophilia model

  • Treatment for all patients
  • Stem cell releasing Factor VIII product
  • Status: in development

Sernova’s Cell Pouch™ with Factor VIII releasing cells:

  • Reduce/eliminate Factor VIII infusions
  • Maintain constant blood levels of

Factor VIII

  • Reduce joint bleeds
  • Improve long-term efficacy
  • Improve QOL

22

slide-23
SLIDE 23

Thyroid Disease Program

Estimated Market $2,2 Billion Thyroid Therapy (Current Standard of Care) Oral – Intravenous – Others Targeted Thyroid Disorders (Thyroidectomy)

  • Grave’s disease
  • Thyroid Nodules (Hyperthyroidism)
  • Hashimoto disease

Therapeutic Goals: Improved efficacy with prophylactic treatment reduced cost; improved patient QOL; reduction of disease side effects Sernova’s Product Approach

  • Thyroidectomy patient cells transplanted into the Cell Pouch
  • Status: Preclinical assessment: Corrected patient cells survive and

produce thyroid hormone Sernova’s Cell Pouch™ Thyroid releasing cells:

  • Reduce/eliminate daily life long thyroid

medications

  • Recover natural feedback loop of

thyroid hormones

  • Reduce side effects from low thyroid

hormone levels

  • Improve long-term efficacy
  • Improve QOL

23

slide-24
SLIDE 24

Collaborations

24

slide-25
SLIDE 25

President and CEO

  • Dr. Philip Toleikis

1-519-858-5126 Info@Sernova.com Corporate Communications Dominic Gray 1-519-858-5126 Dominic.Gray@Sernova.com

TRADED ON

SEOVF

Investor Relations Danny Matthews dmatthews@soleburytrout.com